These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 30305547)

  • 21. Effects of bone marrow mesenchymal stem cells on hematopoietic recovery and acute graft-versus-host disease in murine allogeneic umbilical cord blood transplantation model.
    Li ZY; Wang CQ; Lu G; Pan XY; Xu KL
    Cell Biochem Biophys; 2014 Sep; 70(1):115-22. PubMed ID: 24696072
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential therapeutic applications of mesenchymal stromal cells.
    Larsen S; Lewis ID
    Pathology; 2011 Oct; 43(6):592-604. PubMed ID: 21876470
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population.
    Lucchini G; Introna M; Dander E; Rovelli A; Balduzzi A; Bonanomi S; Salvadè A; Capelli C; Belotti D; Gaipa G; Perseghin P; Vinci P; Lanino E; Chiusolo P; Orofino MG; Marktel S; Golay J; Rambaldi A; Biondi A; D'Amico G; Biagi E
    Biol Blood Marrow Transplant; 2010 Sep; 16(9):1293-301. PubMed ID: 20350611
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mesenchymal stromal cells lose their immunosuppressive potential after allotransplantation.
    Prigozhina TB; Khitrin S; Elkin G; Eizik O; Morecki S; Slavin S
    Exp Hematol; 2008 Oct; 36(10):1370-6. PubMed ID: 18619727
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mesenchymal stem cell-based therapy for autoimmune-related fibrotic skin diseases-systemic sclerosis and sclerodermatous graft-versus-host disease.
    Yang H; Cheong S; He Y; Lu F
    Stem Cell Res Ther; 2023 Dec; 14(1):372. PubMed ID: 38111001
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human placenta-derived mesenchymal stem cells ameliorate GVHD by modulating Th17/Tr1 balance via expression of PD-L2.
    Ma Y; Wang Z; Zhang A; Xu F; Zhao N; Xue J; Zhang H; Luan X
    Life Sci; 2018 Dec; 214():98-105. PubMed ID: 30393022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mesenchymal Stromal Cells for the Treatment of Graft Versus Host Disease.
    Kelly K; Rasko JEJ
    Front Immunol; 2021; 12():761616. PubMed ID: 34764962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mesenchymal stem cells for the treatment and prevention of graft-versus-host disease: experiments and practice.
    Kim N; Im KI; Lim JY; Jeon EJ; Nam YS; Kim EJ; Cho SG
    Ann Hematol; 2013 Oct; 92(10):1295-308. PubMed ID: 23722500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cotransplantation of HLA-identical mesenchymal stem cells and hematopoietic stem cells in Chinese patients with hematologic diseases.
    Zhang X; Li JY; Cao K; Lu H; Hong M; Qian S; Wu H; Liu P; Xu W
    Int J Lab Hematol; 2010 Apr; 32(2):256-64. PubMed ID: 19656235
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Promising cellular therapeutics for prevention or management of graft-versus-host disease (a review).
    McGuirk JP; Weiss ML
    Placenta; 2011 Oct; 32 Suppl 4(0 4):S304-10. PubMed ID: 21658764
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The potential use of mesenchymal stem cells in hematopoietic stem cell transplantation.
    Kim EJ; Kim N; Cho SG
    Exp Mol Med; 2013 Jan; 45(1):e2. PubMed ID: 23306700
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetically engineered mesenchymal stromal cells as a new trend for treatment of severe acute graft-versus-host disease.
    Keshavarz Shahbaz S; Mansourabadi AH; Jafari D
    Clin Exp Immunol; 2022 May; 208(1):12-24. PubMed ID: 35274673
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fetal membrane cells for treatment of steroid-refractory acute graft-versus-host disease.
    Ringdén O; Erkers T; Nava S; Uzunel M; Iwarsson E; Conrad R; Westgren M; Mattsson J; Kaipe H
    Stem Cells; 2013 Mar; 31(3):592-601. PubMed ID: 23307526
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Highlighting the interaction between immunomodulatory properties of mesenchymal stem cells and signaling pathways contribute to Graft Versus Host Disease management.
    Mirfakhraie R; Ardakani MT; Hajifathali A; Karami S; Moshari MR; Hassani M; Firouz SM; Roshandel E
    Transpl Immunol; 2022 Apr; 71():101524. PubMed ID: 34990789
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adipose tissue-derived mesenchymal stromal cells as part of therapy for chronic graft-versus-host disease: A phase I/II study.
    Jurado M; De La Mata C; Ruiz-García A; López-Fernández E; Espinosa O; Remigia MJ; Moratalla L; Goterris R; García-Martín P; Ruiz-Cabello F; Garzón S; Pascual MJ; Espigado I; Solano C
    Cytotherapy; 2017 Aug; 19(8):927-936. PubMed ID: 28662983
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination cell therapy using mesenchymal stem cells and regulatory T-cells provides a synergistic immunomodulatory effect associated with reciprocal regulation of TH1/TH2 and th17/treg cells in a murine acute graft-versus-host disease model.
    Lim JY; Park MJ; Im KI; Kim N; Jeon EJ; Kim EJ; Cho ML; Cho SG
    Cell Transplant; 2014 Apr; 23(6):703-14. PubMed ID: 23452894
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Donor-derived marrow mesenchymal stromal cell co-transplantation following a haploidentical hematopoietic stem cell transplantation trail to treat severe aplastic anemia in children.
    Wang Z-; Yu H-; Cao F-; Liu Z-; Liu Z-; Feng W-; Liu X-; Yu Y-; Xiao Y; Li L-; Zhou J
    Ann Hematol; 2019 Feb; 98(2):473-479. PubMed ID: 30341538
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inducible Costimulator Gene-Transduced Bone Marrow-Derived Mesenchymal Stem Cells Attenuate the Severity of Acute Graft-Versus-Host Disease in Mouse Models.
    Yang D; Wang LP; Zhou H; Cheng H; Bao XC; Xu S; Zhang WP; Wang JM
    Cell Transplant; 2015; 24(9):1717-31. PubMed ID: 25203502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mesenchymal Stromal Cells Stimulate the Proliferation and IL-22 Production of Group 3 Innate Lymphoid Cells.
    van Hoeven V; Munneke JM; Cornelissen AS; Omar SZ; Spruit MJ; Kleijer M; Bernink JH; Blom B; Voermans C; Hazenberg MD
    J Immunol; 2018 Aug; 201(4):1165-1173. PubMed ID: 29980610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Ressarch Advances of Prevantive and Therapeatic Effect of Mesenchymal Stromal Cells on Graft-Versus-Host Disease--Review].
    Wang L; Ma DX; Liu SF; Gao CJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Feb; 27(1):283-287. PubMed ID: 30738484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.